Mary Fenton
Vermögen: 3 Mio $ am 31.08.2026
Vermögen: 3 Mio $ am 31.08.2026
Mary Kay Fenton is currently Director at Connecticut Business & Industry Association since 2018 and Chief Financial Officer at Cullinan Therapeutics, Inc. starting in 2024.
Former roles include Independent Director at Oncorus, Inc. from 2019 to 2023, Vice President-Strategic Operations at Vertex Pharmaceuticals, Inc. from 2019 to 2021, Senior Manager-Technology Industry Group at PricewaterhouseCoopers LLP from 1991 to 2000, CFO, Principal Accounting Officer & Executive VP at Achillion Pharmaceuticals, Inc. from 2016 to 2018, President, Chief Executive & Financial Officer at Talaris Therapeutics, Inc. in 2023, and Chief Operating & Financial Officer at Semma Therapeutics, Inc. in 2019.
Education includes undergraduate studies at College of the Holy Cross (Massachusetts) and an MBA from the University of Connecticut School of Business.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 30.06.2026 | 127’921 ( 0.22% ) | 3 Mio $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Finanzdirektor/CFO | 29.04.2024 |
Connecticut Business & Industry Association
Connecticut Business & Industry Association Miscellaneous Commercial ServicesCommercial Services Operates as a non profit organization that provides commercial support services | Direktor/Vorstandsmitglied | 06.12.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
| TOUE BIOPAR | Vorstandsvorsitzender | 01.10.2023 |
| ONCORUS, INC. | Direktor/Vorstandsmitglied | 27.07.2023 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01.02.2021 |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Develops transformative therapies for patients who currently depend on insulin injections | Finanzdirektor/CFO | 01.10.2019 |
| ACHILLION PHARMACEUTICALS, INC. | Finanzdirektor/CFO | 28.12.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
PricewaterhouseCoopers LLP
PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, assurance, tax and business consulting services | Commercial Services |
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
College of the Holy Cross (Massachusetts)
College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Connecticut Business & Industry Association
Connecticut Business & Industry Association Miscellaneous Commercial ServicesCommercial Services Operates as a non profit organization that provides commercial support services | Commercial Services |
University of Connecticut School of Business
University of Connecticut School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Semma Therapeutics, Inc.
Semma Therapeutics, Inc. BiotechnologyHealth Technology Develops transformative therapies for patients who currently depend on insulin injections | Health Technology |
Oncorus, Inc.
Oncorus, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops next generation immunotherapy platform to treat cancer | Health Technology |
Cullinan Oncology, Inc.
Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen